Article
CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope.
The Journal of clinical investigation - 1 Oct 2008
Skowera Ania, Ellis Richard J, Varela-Calviño Ruben, Arif Sefina, Huang Guo Cai, Van-Krinks Cassie, Zaremba Anna, Rackham Chloe, Allen Jennifer S, Tree Timothy I M, Zhao Min, Dayan Colin M, Sewell Andrew K, Unger Wendy W, Unger Wendy, Drijfhout Jan W, Ossendorp Ferry, Roep Bart O, Peakman Mark
Abstract excerpt
The final pathway of beta cell destruction leading to insulin deficiency, hyperglycemia, and clinical type 1 diabetes is unknown. Here we show that circulating CTLs can kill beta cells via recognition of a glucose-regulated epitope. First, we identified 2 naturally processed epitopes from the human preproinsulin signal peptide by elution from HLA-A2 (specifically, the protein encoded by the A*0201 allele)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
